The use of PTH in the treatment of osteoporosis.
Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.
Borba
Victória Z Cochenski
VZ
Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brasil. Victóriaborba@terra.com
Mañas
Nádila Cecyn Pietszkowski
NC
D045930:Anabolic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001862:Bone Resorption / Q000378:metabolism; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*
D045930:Anabolic Agents; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019379:Teriparatide